¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"adverse drug reaction reporting systems"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • arm tonus reaction
    À§ÆÈ±ÙÀ°±äÀå¹ÝÀÀ
  • Arthus reaction
    ¾Æ¸£Åõ½º¹ÝÀÀ
  • associated reaction
    ¿¬ÇÕ¹ÝÀÀ
  • autoimmune reaction
    ÀÚ°¡¸é¿ª¹ÝÀÀ
  • axon reaction
    Ãà»è¹ÝÀÀ
  • acrosome reaction
    ÷´Üü¹ÝÀÀ
  • activator reaction
    Ȱ¼ºÁ¦¹ÝÀÀ
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute situational stress reaction
    ±Þ¼º»óȲ½ºÆ®·¹½º¹ÝÀÀ
  • addition reaction
    ºÎ°¡¹ÝÀÀ
  • adjustment reaction
    ÀûÀÀ¹ÝÀÀ
  • aerobic reaction
    »ê¼Ò¼º¹ÝÀÀ
  • agglutination reaction
    ÀÀÁý¹ÝÀÀ
  • alarm reaction
    ¾Ë¸²¹ÝÀÀ, °æº¸¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • photoallergic drug eruption
    ±¤¾Ë·¹¸£±â¾à¹°¹ßÁø
  • generic drug name
    ÀϹݾà¸í
  • idiosyncratic drug response
    ƯÀ̾๰¹ÝÀÀ
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • transdermal drug delivery system
    °æÇǾ๰Àü´Þü°è
  • acrosome reaction
    ÷´Üü¹ÝÀÀ
  • activator reaction
    Ȱ¼ºÁ¦¹ÝÀÀ
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼öÇ÷¹ÝÀÀ
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute situational stress reaction
    ±Þ¼º»óȲ½ºÆ®·¹½º¹ÝÀÀ
  • addition reaction
    ºÎ°¡¹ÝÀÀ
  • adjustment reaction
    ÀûÀÀ¹ÝÀÀ
  • aerobic reaction
    È£±â¼º¹ÝÀÀ
  • affective reaction
    Á¤µ¿¹ÝÀÀ
  • agglutination reaction
    ÀÀÁý¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • aerobic reaction
    È£±â¼º ¹ÝÀÀ
  • affective reaction
    Á¤µ¿¹ÝÀÀ, Á¤°¨¹ÝÀÀ
  • agglutination reaction
    ÀÀÁý¹ÝÀÀ(¡­Úãëë).
  • allergic reaction
    ¾Ë·¹¸£±â(¼º) ¹ÝÀÀ.
  • allergic reaction
    ¾Ë·¹¸£±â(¼º) ¹ÝÀÀ.
  • alternative reaction
    ±³´ë¹ÝÀÀ(ÎßÓÛÚãëë).
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã½º¼º ¹ÝÀÀ(¡­Úãëë).
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã¼º ¹ÝÀÀ(¡­Úãëë).
  • anaphylactic reaction
    ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀ(Úãëë),Ãʰú¹Î¹ÝÀÀ
  • anaphylactoid reaction
    ¾Æ³ªÇʶô½Ã½º¾ç ¹ÝÀÀ, °ú¹ÎÁõ¼º ¹ÝÀÀ.
  • anaphylactoid reaction
    ¾Æ³ªÇʶô½Ã¾ç ¹ÝÀÀ, °ú¹ÎÁõ¼º ¹ÝÀÀ.
  • anniversary reaction
    ±â³äÀÏ ¹ÝÀÀ
  • anorectic reaction
    ½Ä¿å°áÇ̹ÝÀÀ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü¹ÝÀÀ
  • antiglobulin reaction
    Çױ۷κҸ°¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • drug eruption
    ¾àÁø(å·òÖ)
  • drug evaluation
    ¾à¹° ¾à¹°Æò°¡(ËâËÑ̰˧).
  • drug exanthem
    ¾àÁø(å·òÖ)
  • drug fever
    ¾à¹°¿­(å·Úªæð).
  • drug habit
    ¸¶¾à±âº®(ئå·ÐîÛþ), ¾à¹°±âº®(å·ÚªÐîÛþ).
  • drug idiosyncrasy
    ¾à¹°Æ¯ÀÌüÁú.
  • drug induced disorder
    ¾à¹°À¯¹ß¼ºÁúȯ
  • drug induced urticaria
    ¾à¹° À¯¹ß µÎµå·¯±â
  • drug industry
    ¾à¹° Á¦¾à°ø¾÷(Ì¡ËâË­Ëâ).
  • drug interaction
    ¾à¹° »óÈ£ÀÛ¿ë
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë.
  • drug interaction
    ¾à¹°»óÈ£ÀÛ¿ë(å·ÚªßÓû»íÂéÄ).
  • drug interference
    ¾à¹°°£¼·
  • drug level monitoring
    ¾à¹°³óµµ°¨½Ã, ¾à¹°³óµµÃøÁ¤
  • drug metabolism
    ¾à¹°´ë»ç
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
  • reaction mixture
    ¹ÝÀÀ È¥ÇÕ¹°(ÚãëëûèùêÚª)
  • reaction of identity
    µ¿Áú¼º ¹ÝÀÀ(ÔÒòõàõÚãëë)
  • reaction of nonidentity
    ÀÌÁú¼º ¹ÝÀÀ(ì¶òõàõÚãëë)
  • reaction of partial identity
    ºÎºÐ µ¿Áú¼º(Ý»ÝÂÔÒòõàõ) ¹ÝÀÀ(Úãëë)
  • reaction order
    ¹ÝÀÀÂ÷¼ø(Úãëëó­â÷)
  • reaction paper cheomatography
    ¹ÝÀÀ ¿©Áö(Úãëëæ¤òµ) Å©·Î¸¶Åä±×·¡ÇÇ
  • reaction rate
    ¹ÝÀÀ ¼Óµµ·Ð(ÚãëëáÜÓøÖå)
  • rearrangement reaction
    Àç¹è¿­ ¹ÝÀÀ(î¢ÛÕÖªÚãëë)
  • reversible reaction
    °¡¿ª ¹ÝÀÀ(Úãëë)
  • Sakaguchi reaction
    »çÄ«±¸Âî ¹ÝÀÀ(Úãëë)
  • Salkowski reaction
    »ìÄÚÇÁ½ºÅ° ¹ÝÀÀ(Úãëë)
  • Sanger reaction
    »ý°Å ¹ÝÀÀ(Úãëë)
  • scalar reaction
    ½ºÄ®¶ó ¹ÝÀÀ(Úãëë)
  • Schardinger reaction
    »þ¸£µù°Å ¹ÝÀÀ(Úãëë)
  • second-order reaction
    ÀÌÂ÷ ¹ÝÀÀ(ì£ó­Úãëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
DR degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit...
DRMS drug reaction monitoring system
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
DAST drug abuse screening test; drug and alcohol screening test
DD dangerous drug; data definition; day of delivery; degenerated disc; degenerative disease; delusional...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 8
DD Drug discrimination
DLST Drug lymphocyte stimulation test
DME drug metabolizing enzyme
DUE Drug usage evaluation
DIP Drug-induced Parkinsonism
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • protein-drug complex
    ´Ü¹é-¾à¹° º¹ÇÕü
  • storage of drug
    ¾à¹°ÀÇ º¸°ü
  • sulfa drug
    ¼³ÆÄÁ¦
  • sustained action drug
    ÁöÈ¿¼º ¾àÁ¦
  • sustained release drug
    ÁöÈ¿¼º ¾àÁ¦
  • topical dental drug
    µµÆ÷¿ë Ä¡°ú ¾àÁ¦
  • tranquilizing drug
    Á¤¿ÂÁ¦, Á¤½Å ¾ÈÁ¤Á¦
    °¨Á¤ »óÅ¿¡ ÀÛ¿ëÇÏ´Â ¾à¹°·Î¼­, ȯÀÚÀÇ ÀǽÄÀ» ȥʽÃŰÁö ¾Ê°í Á¶¿ëÈ÷ ¶Ç´Â Æò¿ÂÇÏ°Ô ÇÏ´Â °Í. À̰ÍÀº ±Ù½É, °ÆÁ¤ »óÅÂ, ½Å°æÁõ ¹× Á¤½Å Àå¾Ö µîÀÇ Ä¡·á¿¡ »ç¿ëµÈ´Ù.
  • untoward drug effect
    ¾à¹°ÀÇ ¹Ù¶÷Á÷ÇÏÁö ¾Ê´Â È¿°ú
    ¿ì¸®°¡ ¿øÇÏ´Â Ä¡·á ¸ñÀû¿¡ ºÎÇÕÇÏ´Â ¾à¸® ÀÛ¿ëÀÌ ¾Æ´Ï¶ó ÀÎü¿¡ ÇØ°¡µÇ´Â µ¶ ÀÛ¿ë ¶Ç´Â ºÎÀÛ¿ë.
  • Abderhalden's reaction
    ¾Ðµ¥¸£ÇÒµ§ ¹ÝÀÀ
    ÀÌÁ¾ ´Ü¹éÁúÀÌ Ç÷¾× Áß¿¡ ħÀÔÇϸé, »ýü´Â À̰ÍÀ» ºÐÇØÇÏ´Â È¿¼Ò¸¦ »ý»êÇÔÀ¸·Î½á ÀÀ´äÇÑ´Ù´Â ±¸ °¡¼³¿¡ ±âÃÊÇÑ Ç÷û ¹ÝÀÀÀÌ´Ù. ÀÌ·¯ÇÑ ¹æ¾î È¿¼Ò´Â
  • accelerated reaction
    ÃËÁø ¹ÝÀÀ, °¡¼Ó ¹ÝÀÀ
    º¸Åë ¶§º¸´Ù ´Ü ½Ã°£ ³»¿¡ ÀϾ´Â ¹ÝÀÀ.
  • acute hemolytic transfusion reaction
    ±Þ¼º ¿ëÇ÷¼º ¼öÇ÷ ¹ÝÀÀ
  • acute phase reaction
    ±Þ¼º±â ¹ÝÀÀ
  • acute situational stress reaction
    ±Þ¼º »óȲ¼º ½ºÆ®·¹½º ¹ÝÀÀ
    ±ØµµÀÇ È¯°æÀû ½ºÆ®·¹½º¿¡ ´ëÇÑ ÀϽÃÀûÀÎ ¹ÝÀÀÀ¸·Î ±âÃÊÀûÀÎ Á¤½Å Àå¾Ö°¡ ¾ø´Â °³Àο¡°Ô ³ªÅ¸³­´Ù.
  • addition reaction
    ÷°¡ ¹ÝÀÀ
  • adhesion reaction
    À¯Âø ¹ÝÀÀ, ºÎÂø ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 8
drug-fast Pertaining to microorganisms that resist or become tolerant to an antibacterial agent.
(05 Mar 2000)
drug fever Fever resulting from an allergic reaction to a drug that clears rapidly on discontinuation of the drug.
(05 Mar 2000)
drug half-life The amount of time it takes for one-half of an administered drug to be lost through biological processes (metabolism and elimination).
(27 Sep 1997)
drug holiday Interval when a chronically medicated patient temporarily stops taking the medication; used to allow some recuperation of normal functions, to maintain sensitivity to the drug, and to reduce the likelihood of side-effects.
(05 Mar 2000)
drug hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
(12 Dec 1998)
drug implants Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
(12 Dec 1998)
drug incompatibility <pharmacology> The quality of not being miscible with another given substance without a chemical change.
One drug is not of suitable composition to be combined or mixed with another agent or substance. The incompatibility usually results in an undesirable reaction, including chemical alteration or destruction.
(12 Dec 1998)
drug-induced cholestasis <hepatology> A condition where a drug is interfering with the normal flow of bile from the liver to the gut via the biliary tract. The end result is jaundice.
Origin: Gr. Stasis = stoppage
(27 Sep 1997)
drug-induced diarrhoea <gastroenterology> Diarrhoea may be produced by several mechanisms. Laxatives may produce diarrhoea by increasing the flow of water into the intestine or by increasing the intestinal motility.
Antibiotic medications can cause diarrhoea by killing the normal bacteria that live in the intestine and help us digest our food. Some drugs produce diarrhoea as a side effect or as drug toxicity.
(27 Sep 1997)
drug-induced disease <pharmacology> A toxic reaction to or morbid condition resulting from the administration of a drug.
(05 Mar 2000)
drug-induced eosinophilic lung disease <radiology> Diffuse reticular pattern: nitrofurantoin, Loeffler-like pattern: penicillin, sulfonamides, ASA, para-ASA, imipramine, HCTZ, cromolyn sodium see: eosinophilic lung disease
(12 Dec 1998)
drug-induced hepatitis <hepatology, pathology> Inflammation and hepatocellular damage of the liver that is caused by a drug.
Some medications may cause inflammation of the liver as a drug side effect or drug toxicity. Drugs that are known to cause hepatitis include acetaminophen, isoniazid, halothane, methyldopa, erythromycin and oral contraceptives.
(27 Sep 1997)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
drug-induced tremor <neurology, pharmacology> A drug-induced condition where there is shaking (tremor) of the extremities that is increased with purposeful movement.
Drugs known to induce tremor include: theophylline, Alupent, cyclosporine, amphetamines, lithium and caffeine.
(27 Sep 1997)
drug industry That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 8
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 8
ÅëÇÕ°Ë»ö ¿Ï·á